Skip to Content

CureVac NV Ordinary Shares CVAC Stock Quote

| Rating as of

Morningstar‘s Stock Analysis CVAC

Valuation
Currency in USD

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

CureVac Focuses on Expanding Pipeline Through Enhanced Oncology Strategy; $15.40 FVE Retained

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

CureVac is working to expand its pipeline by furthering its cancer vaccine capabilities. CureVac acquired Amsterdam-based Frame Cancer Therapeutics for EUR 32 million. Frame Cancer Therapeutics is a private company focused on identifying neoantigens across different cancer types. CureVac also established a partnership with Belgium-based myNEO to develop mRNA-based cancer vaccines using myNEO’s tumor antigen discovery platform. This acquisition and partnership help to enhance CureVac’s oncology capabilities, but it’s too soon to forecast the impact of these new platforms since they are in very early research and development phases.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CVAC

Company Profile CVAC

Business Description

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac’s first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Contact
Friedrich-Miescher-Strasse 15
Tubingen, BW, 72076, Germany
T +49 707198830
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type
Employees 900